Core Insights - Heartflow, Inc. will release its financial results for Q3 2025 on November 12, 2025, after market close, followed by a conference call at 1:30 p.m. PT / 4:30 p.m. ET [1] Company Overview - Heartflow is a leader in AI technology for coronary artery disease (CAD), transforming CAD management through early detection, accurate diagnosis, and lifelong management [4] - The Heartflow One platform utilizes AI to convert coronary CTA images into personalized 3D heart models, providing actionable insights into plaque characteristics and their impact on blood flow without invasive procedures [4] - The company has a robust data pipeline with over 110 million annotated CTA images and has been validated through over 100 studies involving more than 365,000 patients, achieving a coronary CTA image acceptance rate exceeding 96% [3] Technology and Research - Heartflow's technology is supported by ACC/AHA guidelines and over 600 peer-reviewed publications, demonstrating its effectiveness in clinical practice [3] - The integrated workflow of Heartflow allows for instant analysis upon order, facilitating timely clinical decision-making [3] - The company adheres to stringent global security regulations, ensuring the integrity and security of patient data [3]

Core Insights - Heartflow, Inc. has introduced the Heartflow PCI Navigator, an AI-driven tool designed to enhance percutaneous coronary interventions (PCI) planning by providing interventional cardiologists with a patient-specific 3D model that integrates anatomy, plaque composition, and lesion-specific physiology [1][4][11] - The PLAN CALCIUM study will be presented at the TCT 2025 conference, showcasing how AI-powered plaque analysis can influence decisions in managing highly calcified lesions during PCI [6][2] - The NAVIGATE-PCI registry will enroll approximately 2,500 patients across 30 sites to evaluate the impact of CT-guided PCI planning on physician confidence, procedural safety, and patient outcomes [8][9] Company Overview - Heartflow is a leader in AI technology for coronary artery disease (CAD), with a focus on transforming how clinicians manage care through innovative solutions [11] - The company has a robust data pipeline built from over 110 million annotated CTA images, supporting its AI-driven solutions that have been validated through over 100 studies involving more than 365,000 patients [10][11] - Heartflow's technology is backed by ACC/AHA guidelines and has been proven in real-world practice, achieving coronary CTA image acceptance rates exceeding 96% [10] Product Features - PCI Navigator integrates essential measurements, including IVUS-like and FFR-like visualizations, into a seamless web-based interface, streamlining the decision-making process in the cath lab [3][5] - The tool enhances planning by providing insights into lesion-specific physiology, stent landing zones, and optimal outcomes, thereby improving procedural efficiency and clinical confidence [7][5] Research and Development - The PLAN CALCIUM study demonstrated that AI-powered plaque analysis can significantly alter plans for calcium modification in over half of the lesions evaluated, indicating the potential for more precise coronary interventions [6][8] - The NAVIGATE-PCI registry aims to address unmet needs in PCI planning and is expected to lead to broader clinical use of PCI Navigator by 2026 [9][8]

Heartflow PCI Navigator Heartflow PCI Navigator is the only integrated, AI-driven percutaneous coronary interventions planning tool that gives interventional cardiologists a patient-specific 3D model—detailing anatomy, plaque composition, and lesion-specific physiology—all aligned to optimize potential stent placement. PLAN CALCIUM study to be presented at TCT 2025 conference highlights how AI-powered plaque analysis can inform lesion preparation and calcium modification planning NAVIGATE-PCI registry t ...